Jump to main content
Jump to site search

Issue 3, 2012
Previous Article Next Article

The discovery of novel 10,11-dihydro-5H-dibenz[b,f]azepine SIRT2 inhibitors

Author affiliations

Abstract

Isoform selective inhibitors of the sirtuins (NAD+-dependent histone deacetylases) should enable an in depth study of the molecular biology underpinning these targets and how they are deregulated in diseases such as cancer and neurodegeneration. Herein, we present the discovery of structurally novel SIRT2 inhibitors. Hit molecule 8 was discovered through the chemical synthesis and biological characterization of a small-molecule compound library based around the 10,11-dihydro-5H-dibenz[b,f]azepine scaffold. In vitro screening assays revealed compound 8 to have an IC50 of 18 μM against SIRT2 and to exhibit more than 30-fold selectivity compared to SIRT1. Cellular assays, performed on MCF-7 cells, confirmed the in vitro selectivity and showed hit 8 to have antiproliferative activity at a concentration of 30 μM. Computational studies were performed to predict the SIRT2 binding mode and to rationalise the observed selectivity.

Graphical abstract: The discovery of novel 10,11-dihydro-5H-dibenz[b,f]azepine SIRT2 inhibitors

Back to tab navigation

Supplementary files

Article information


Submitted
21 Nov 2011
Accepted
22 Dec 2011
First published
04 Jan 2012

Med. Chem. Commun., 2012,3, 373-378
Article type
Concise Article

The discovery of novel 10,11-dihydro-5H-dibenz[b,f]azepine SIRT2 inhibitors

P. Di Fruscia, K. Ho, S. Laohasinnarong, M. Khongkow, S. H. B. Kroll, S. A. Islam, M. J. E. Sternberg, K. Schmidtkunz, M. Jung, E. W.-F. Lam and M. J. Fuchter, Med. Chem. Commun., 2012, 3, 373
DOI: 10.1039/C2MD00290F

Search articles by author

Spotlight

Advertisements